Clinical/Molecular RiskDirected Therapy for Newly Diagnosed Medulloblastoma
A Clinical And Molecular Risk-Directed Therapy For Newly Diagnosed Medulloblastoma
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Parker, Melanie
Trial Phone: 321.841.5357 ; 321-841-7561
-
IRB No: 13.198.12
Protocol Abbrev: SJMB12
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Pediatric
Secondary Protocol No: SJMB12
Treatment: Radiation: Craniospinal Irradiation Other: Aerobic Training Other: Neurocognitive Remediation Drug: Chemotherapy (multiple)
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT01878617
-
Objective
To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study
-
Key Eligibility
Ages Eligible for Study:
-3 Years to 21 Years
-Genders Eligible for Study: Both
-Accepts Healthy Volunteers: No
